Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pediatric study of SHP647

Next Previous
X
Search
Trial Profile

Pediatric study of SHP647

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ontamalimab (Primary)
  • Indications Crohn's disease; Ulcerative colitis
  • Focus Therapeutic Use

    • Most Recent Events

    • 28 May 2020 According to an Takeda media release, the Crohn's & Colitis Foundation will serve as an independent body to review requests from investigators and physicians seeking access to anonymised SHP647 clinical trial data and biosamples, and to make final decisions on data sharing.
    • 28 May 2020 According to an Takeda media release, subject to obtaining trial participant consents and the satisfaction of regulatory and ethical considerations, Takeda will make SHP647 clinical trial data and biosamples available to the scientific community through the Crohn's & Colitis Foundation via the IBD Plexus platform.
    • 28 May 2020 According to an Takeda media release, patients should continue to adhere to the current study protocol until contacted by their study site after guidance has been provided by the Takeda study team members.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top